Logo

Janssen Reports the BLA Submission of Talquetamab to the US FDA for the Treatment of Relapsed or Refractory Multiple Myeloma

Share this

Janssen Reports the BLA Submission of Talquetamab to the US FDA for the Treatment of Relapsed or Refractory Multiple Myeloma

Shots:

  • The company has submitted the BLA to the US FDA for talquetamab, an off-the-shelf, bispecific T-cell engager Ab targeting both GPRC5D for r/r MM. The BLA was based on the P-I/II (MonumenTAL-1) study evaluating talquetamab
  • As of data cut off May 16, 2022, ORR was 73% in 143 patients treated at 0.4mg/kg, qw, responses were & deepened over time, the median time to response was 1.2mos., the median time to CR was 2.1mos., m-DOR (9.3mos.), m-PFS (7.5mos.), ORRs in patients who were triple-class refractory (72%) and Penta-drug refractory (71%) over the overall population, no significant effect on PK, efficacy, or AEs were seen. The results were presented at ASH 2022 in an oral scientific session
  • Talquetamab received BTD from the US FDA for r/r MM & also received ODD from the US FDA & EC

Ref: PRNewswire Image: Janssen

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions